IL-7Rα was found to be upregulated in the cells of relapsed patients, and a good efficacy was observed in anti-IL-7Rα monoclonal antibodies in relapsed T-ALL patient-derived xenografts (PDXs) [14]. Here, IL7R is linked to acute lymphoblastic leukemia.